Revisiones_bibliográficas TyO

Google+

martes, 22 de agosto de 2017

Resultados de la Artroplastia Total del Codo en Pacientes Menores de 50 Años.

http://www.mihombroycodo.com.mx/academia/resultados-de-la-artroplastia-total-del-codo-en-pacientes-menores-de-50-anos/

Results of Total Elbow Arthroplasty in Patients Less Than 50 Years Old.

Fuente

Este artículo es publicado originalmente en:

https://www.ncbi.nlm.nih.gov/pubmed/28823536

http://www.jhandsurg.org/article/S0363-5023(16)31132-7/fulltext

De:

Schoch B1,Wong J2,Abboud J2,Lazarus M2,Getz C2,Ramsey M3.

J Hand Surg Am.

2017 Aug 16. pii: S0363-5023(16)31132-7. doi: 10.1016/j.jhsa.2017.06.101. [Epub ahead of print]

Copyright © 2017 American Society for Surgery of the Hand. Published by Elsevier Inc. All rights reserved.

Abstract

PURPOSE:

Total elbow arthroplasty (TEA) is a treatment option for end-stage arthritis in low-demand patients willing to accept the limitations of TEA. Concern remains regarding the longevity of TEA implants, especially in younger patients. The purpose of this study was to determine the failure rate and complication profile of TEA performed in patients aged less than 50 years.

CONCLUSIONS:

High rates of early mechanical failure, predominately ulnar loosening, were observed in TEA in patients aged less than 50 years. Surgeons should remain cautious in performing TEA in young patients who can be expected to use the TEA in a more demanding fashion, placing them at higher risk for mechanical failure.

KEYWORDS:

Complications; mechanical failure; revision; total elbow arthroplasty; young

aResumen

PROPÓSITO:
La artroplastia total del codo (TEA) es una opción de tratamiento para la artritis en estadio terminal en pacientes de baja demanda dispuestos a aceptar las limitaciones de TEA. La preocupación sigue siendo respecto a la longevidad de los implantes de TEA, especialmente en pacientes más jóvenes. El propósito de este estudio fue determinar la tasa de fracasos y el perfil de complicaciones de la TEA realizada en pacientes menores de 50 años.

CONCLUSIONES:
Se observaron altas tasas de fallo mecánico temprano, predominantemente aflojamiento cubital, en TEA en pacientes menores de 50 años. Los cirujanos deben seguir siendo cautelosos en la realización de TEA en pacientes jóvenes que se puede esperar para utilizar el TEA de una manera más exigente, poniendo a ellos en mayor riesgo de falla mecánica.

PALABRAS CLAVE:
Complicaciones; falla mecánica; revisión; Artroplastia total del codo; joven

PMID: 28823536 DOI:

10.1016/j.jhsa.2017.06.101

#artroplastia #codo

Tromboprofilaxis en la cirugía de columna

http://www.cirugiavertebral.com.mx/academia/tromboprofilaxis-en-la-cirugia-de-columna/

Thromboprophylaxis in Spinal Surgery

Fuente

Este artículo es originalmente publicado en:

https://www.ncbi.nlm.nih.gov/pubmed/28820759

https://insights.ovid.com/crossref?an=00007632-900000000-95398

De:

Mosenthal WP1,Landy DC,Boyajian HH,Idowu OA,Shi LL,Ramos E,

Lee MJ.

Spine (Phila Pa 1976).

2017 Aug 17. doi: 10.1097/BRS.0000000000002379. [Epub ahead of print]

Some content from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Abstract

STUDY DESIGN:

Systematic review and meta-analysis

OBJECTIVE.: Determine the incidence of deep vein thrombosis (DVT) and pulmonary embolism (PE) in spinal surgery patients receiving no thromboprophylaxis, mechanoprophylaxis, and chemoprophylaxis.

SUMMARY OF BACKGROUND DATA:

The incidence of thromboembolic complications after spinal surgery is not well established. While a variety of effective mechanical and chemical thromboprophylaxis interventions exist, their role in spinal surgery remains unclear. Spinesurgeons are faced with the difficult decision of balancing the risk of death from a thromboembolic complication against the risk of permanent neurological damage from an epidural hematoma.

CONCLUSIONS:

While the incidence of DVT and PE was relatively low regardless of prophylaxis type, the true incidence is difficult to determine given the heterogeneous nature of the small number of studies available in the literature. Our findings suggest there may be a role for chemoprophylaxis given the relatively high rate of fatal PE. Future studies are needed to determine which patient population would benefit most from chemoprophylaxis.

Resumen

DISEÑO DEL ESTUDIO:
Revisión sistemática y metaanálisis

OBJETIVO .: Determinar la incidencia de trombosis venosa profunda (TVP) y embolismo pulmonar (PE) en pacientes de cirugía de columna que no reciben tromboprofilaxis, mecanoprofilaxis y quimioprofilaxis.

RESUMEN DE DATOS ANTERIORES:
La incidencia de complicaciones tromboembólicas después de la cirugía de columna no está bien establecida. Aunque existe una variedad de intervenciones mecánicas y químicas efectivas de tromboprofilaxis, su papel en la cirugía de la columna no está claro. Los cirujanos de columna se enfrentan con la difícil decisión de equilibrar el riesgo de muerte de una complicación tromboembólica contra el riesgo de daño neurológico permanente por un hematoma epidural.

CONCLUSIONES:
Si bien la incidencia de la TVP y la EP fue relativamente baja independientemente del tipo de profilaxis, la verdadera incidencia es difícil de determinar dada la heterogeneidad del pequeño número de estudios disponibles en la literatura. Nuestros hallazgos sugieren que puede haber un papel para la quimioprofilaxis dada la tasa relativamente alta de PE mortal. Se necesitan estudios futuros para determinar qué población de pacientes se beneficiaría más de la quimioprofilaxis.

PMID: 28820759 DOI:

10.1097/BRS.0000000000002379

#Tromboprofilaxis #cirugía de columna #trombosis venosa profunda #embolismo pulmonar #mecanoprofilaxis #quimioprofilaxis

Deformidades de la columna – Llegar a una perspectiva 3D

http://www.cirugiavertebral.com.mx/academia/deformidades-de-la-columna-llegar-a-una-perspectiva-3d/

3D perspective in Spine Deformity by Jean Dubousset

Fuente

Este artículo y/o video es publicado originalmente en:

https://youtu.be/W-HH45J210s

Courtesy: The Seattle Science Foundation, www.seattlesciencefoundation.orgPublicado el 24 jun. 2017

http://www.seattlesciencefoundation.org

Seattle Science Foundation is a non-profit organization dedicated to the international collaboration among physicians, scientists, technologists, engineers and educators. The Foundation’s training facilities and extensive internet connectivity have been designed to foster improvements in health care through professional medical education, training, creative dialogue and innovation.

NOTE: All archived recorded lectures are available for informational purposes only and are only eligible for self-claimed Category II credit. They are not intended to serve as, or be the basis of a medical opinion, diagnosis, prognosis, or treatment for any particular patient.

Categoría
Licencia

Ciencia y tecnología

Licencia de YouTube estándar

#columna vertebral #deformidades 3D

Miocardiopatía periparto / Peripartum cardiomyopathy

Agosto 18, 2017. No. 2784

La miocardiopatía periparto como causa de insuficiencia cardiaca en el embarazo y el puerperio

Margarita Gallardo Arozena, Tania de Ganzo Suarez, Beatriz Contreras Gonzalez, Ivan Bernaldo de Quiros Huguet, Nieves Sierra Medina y Domingo Mendez Mora

Prog Obstet Ginecol. 2015;58(8):363-367

Resumen

La miocardiopatía periparto es una enfermedad con una elevada morbimortalidad y que, a pesar de sus riesgos potenciales, no es posible prevenirla. Por ello, solo podremos actuar sobre los factores de riesgo asociados a su aparición y sobre las complicaciones una vez diagnosticada. Debido a su baja incidencia, es difícil el conocimiento real de esta enfermedad, ya que se basa en artículos publicados sobre series reducidas de casos. El propósito de esta revisión es realizar una descripción de la fisiopatología, las manifestaciones clínicas, el diagnóstico y el tratamiento de la enfermedad, enfocada principalmente en el manejo obstétrico de la gestante

PDF

Tratamiento práctico de la cardiomiopatía periparto

Practical management of peripartum cardiomyopathy.

Kim MJ1, Shin MS2.

Korean J Intern Med. 2017 May;32(3):393-403. doi: 10.3904/kjim.2016.360. Epub 2017 Apr 14.

Abstract

Peripartum cardiomyopathy (PPCM) is an idiopathic cardiomyopathy that causes systolic heart failure (HF) in previously healthy young women. Despite latest remarkable achievement, unifying pathophysiologic mechanism is not well established. Considering close temporal relationship to pregnancy, the recent prolactin theory is promising. Abnormal short form of 16-kDa prolactin may be produced in the oxidative stress milieu, show anti-angiogenic effect and damage cardiovascular structure in late pregnancy. Future study is needed to determine whether abnormal prolactin system is useful as a biomarker for diagnosis and therapy of PPCM. Diagnosis is made based on the finding of left ventricular systolic dysfunction after excluding other causes of HF. A multidisciplinary team approach is essential for acute HF, antepartum, labor and postpartum care. Recovery from left ventricular dysfunction is critical for prognosis. As PPCM can recur and cause serious clinical events, subsequent pregnancy is not recommended. This review focuses on the practical management of PPCM.

KEYWORDS: Cardiomyopathies; Heart failure; Peripartum cardiomyopathy; Pregnancy

PDF

Miocardiopatía periparto

Peripartum Cardiomyopathy.

Arany Z1, Elkayam U2.

Circulation. 2016 Apr 5;133(14):1397-409. doi: 10.1161/CIRCULATIONAHA.115.020491.

Abstract

Peripartum cardiomyopathy is a potentially life-threatening pregnancy-associated disease that typically arises in the peripartum period and is marked by left ventricular dysfunction and heart failure. The disease is relatively uncommon, but its incidence is rising. Women often recover cardiac function, but long-lasting morbidity and mortality are not infrequent. Management of peripartum cardiomyopathy is largely limited to the same neurohormonal antagonists used in other forms of cardiomyopathy, and no proven disease-specific therapies exist yet. Research in the past decade has suggested that peripartum cardiomyopathy is caused by vascular dysfunction, triggered by late-gestational maternal hormones. Most recently, information has also indicated that many cases of peripartum cardiomyopathy have genetic underpinnings. We review here the known epidemiology, clinical presentation, and management of peripartum cardiomyopathy, as well as the current knowledge of the pathophysiology of the disease.

KEYWORDS: cardiomyopathies; heart failure; pre-eclampsia; pregnancy

PDF